Bacteria can send signals of satiety to the brain from the gut by molecularly mimicking satiety hormones, thus activating natural satiety pathways. The basis of the technology is a commensal, enterobacteria probiotic strain, Hafnia alvei HA4597™, that produces the ClpB protein, a mimetic of the satiety hormone α-MSH. The pre-clinical data have demonstrated the beneficial anti-obesity effects of Hafnia alvei 4597™ in mice.

Treatment with Hafnia alvei4597™ was associated with decreased body weight and fat mass gain along with reduced food intake as well as positive effects on glycemia and OGTT. A randomized, multicentric, double-blind, placebo controlled clinical trial in 240 subjects has been completed. The trial met the primary endpoint:  statistical difference in the proportion of subjects who lost at least 3% of body weight at 12 weeks. Amongst other findings, the mechanism of action is confirmed by achieving secondary endpoints such as an increase in the feeling of fulness in the verum group.  

This talk covers ProbioSatys’ journey from its preclinical and clinical stage to commercialized product, EnteroSatys, including formulation, manufacturing, and control. First results of clinical trial will be presented and discussed.

Gregory Lambert – CEO – Targedys